Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma

Clinical trial NCT03011814 · RECRUITING

Trial details

NCT number: NCT03011814
Sponsor: City of Hope Medical Center
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Folliculotropic Mycosis Fungoides Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma Recurrent Mycosis Fungoides Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma Refractory Mycosis Fungoides Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified Sezary Syndrome Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma

Start date: 2017-03-08
Primary completion: 2030-04-14
Enrollment: 78

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.